All Updates

All Updates

icon
Filter
FDA approval
Better Therapeutics obtains FDA approval for digital behavioral therapeutic device
Preventive Healthcare
Jul 11, 2023
This week:
Product updates
Alibaba Cloud launches revamped full-stack AI infrastructure to support development of AI models
Generative AI Infrastructure
Today
Funding
Twelve raises USD 645 million in funding to transform CO2 into jet fuel
Alternative Energy
Yesterday
Funding
Air Company raises USD 69 million in Series B funding to commercialize carbon utilization technology
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
Twelve raises USD 645 million in funding to transform CO2 into jet fuel
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LinkGevity receives TechEU grant to accelerate technology developments for AI drug discovery
AI Drug Discovery
Yesterday
Partnerships
CS Genetics and Rosalind partner to enhance single-cell genomic R&D
Precision Medicine
Yesterday
Funding
Hippocratic AI raises USD 17 million in extended Series A funding from NVentures
Generative AI Applications
Yesterday
Partnerships
Industry news
Tallinn partners with Hayden AI to pilot automated bus lane monitoring
Smart Mobility Information
Yesterday
Product updates
Alibaba releases over 100 open-source AI models and text-to-video tool
Foundation Models
Yesterday
Partnerships
Product updates
AssemblyAI partners with Activepieces to offer speech AI capabilities
Foundation Models
Yesterday
Preventive Healthcare

Preventive Healthcare

Jul 11, 2023

Better Therapeutics obtains FDA approval for digital behavioral therapeutic device

FDA approval

  • Prescription digital therapeutics startup Better Therapeutics has obtained FDA authorization for its prescription-only digital behavioral therapeutic device, AspyreRx.

  • AspyreRx is designed to provide cognitive behavioral therapy to adults with type 2 diabetes. The device showed statistically significant reductions in HbA1c levels in a randomized controlled study. Users of AspyreRx experienced cardiometabolic enhancements such as reduced blood pressure, weight, and improved quality of life scores and fasting blood glucose levels. The company plans to launch the device commercially in the fourth quarter of this year.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.